1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Patient characteristics
Characteristic
Age (mean) (range) (yr)55.7 (30–86)
SexM/F = 10:10
Follow-up period (mean) (range) (mo)20.4 (1–62)
Clinical stage (No.)
    ≤II0
    III3
    IV17
CTCAE grade (No.)
    0–20
    320
    4, 50
ICIs (No.)
    Ipilimumab + nivolumab11
    Ipilimumab9
Main physical symptoms (No.)
    Headache13
    Fatigue/malaise3
    Nausea/vomiting2
    Edema1
    Numbness1
    Loss of vision/visual field disorder0
    Diabetes insipidus0
    No symptom0